FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report

The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, though a spokesperson for the HHS did not confirm the news.